- Bone marrow transplant
- CAR T-cell therapy
- Stem cell transplant
Saar I. Gill, MD, PhD
About me
- Scientific Co-Director, Cell Therapy and Transplant Program
- Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
My education and training
- Medical School: University of Melbourne
- Residency: St. Vincent's Hospital Melbourne
- Residency: St Vincents Hospital Sydney
- Fellowship: Peter MacCallum Cancer Centre
- Fellowship: University of Pennsylvania Health System
Spoken languages
Reviews
53 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Qualifications and experience
- American Society for Clinical Oncology (ASCO), International
- American Society of Blood and Marrow Transplantation, International
- American Society of Hematology, International
- American Society of Hematology (ASH), National
- Penn Bone Marrow Transplant and Stem Cell Transplant Program
- Penn Cellular Therapy and Transplant Program
- Penn Hematological Malignancies (Blood Cancer) Program
- Penn Leukemia Program
- Penn Telomere Biology Disorders Program
Treatments and conditions
Research
Publications
Blumenberg V, Diorio C, Gauthier J, Agrusa JE, Dreyzin A, Hänel G, Espinoza-Gutarra MR, Geer M, Perales MA, Ramakrishna S, Jain MD, Gill S, Locke FL, Shouval R, Subklewe M, Komanduri KV, Chapuis AG, Paczesny S, Rejeski K, Shah NN. Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells , Transplant Cell Ther: 2026
Durgin JS, Seo SH, Kazmi S, Valentić B, Leff C, Markovska M, Jin X, Shen F, Berjis A, Mukherjee N, Sannecy A, Plesa G, Gabunia K, Scholler J, Gill SI, O'Connor RS, June CH, Ghassemi S. Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence , Blood: 2026
Chen GM, Jain A, Gering DT, Satulovsky J, Datta S, Lai P, Karar J, Gonzalez VE, Alexander K, Chew A, Jadlowsky JK, Ruella M, Paruzzo L, Amses KR, Rech AJ, Stadtmauer EA, Frey NV, Hexner EO, Porter DL, Cohen AD, Gill SI, Garfall AL, Schuster SJ, Mo KC, Liang SI, Spasic M, Levine BL, Siegel DL, Ramírez-Fernández A, Cabanski CR, Yang E, Mackall CL, Bushman FD, Good Z, John Wherry E, June CH, Fraietta JA. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer , Nat Biomed Eng: 2026
Altun B, Zhao G, Wang B, Mao X, Manfredo-Vieira S, Willis E, Radaelli E, Goodman EE, Boesteanu AC, Gill SI, Patel DR, Wong S, Cottman-Thomas E, Hogan JJ, Payne AS. Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells , Kidney Int: 2026
Bot A, Stephan MT, Gill S. The dawn of in vivo immune cell engineering in oncology , Nat Biotechnol: 2026
Bowman M, Gounder S, Singh V, Shestova O, Robinson T, Zhang A, Gandhi A, Bandopadhyay R, Cai SF, Levine RL, Gill SI, Miles LA, Bowman RL. scDNA: Single Cell DNA analysis software toolkit for subclonality discovery and assessment , bioRxiv: 2025
McFarland AG, Ooi SK, Tafuri D, Kamali E, Cooper N, Cook EJ, Reddy S, Jarocha D, Wellhausen N, Gill SI, Roche AM, Fraietta JA, Bushman FD, Herbst F. An integrated enzymatic and computational pipeline for quantifying off-target base-editing , bioRxiv: 2025
Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble AJ, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velasquez MP, Gill SI. International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AML , Blood Adv, 9: 2025,6047-6058
Mellors PW, Lange AN, Casino Remondo B, Shestov M, Planer JD, Peterson AR, Ying Y, Zhou S, Christie JD, Diamond JM, Cantu E, Basil MC, Gill S. Shared roles of immune and stromal cells in the pathogenesis of human bronchiolitis obliterans syndrome , JCI Insight, 10: 2025,e176596
Sande CM, Chen S, Mitchell DV, Lin P, Abraham DM, Cheng JM, Gebhard T, Deolikar RJ, Freeman C, Zhou M, Kumar S, Bowman M, Bowman RL, Zheng S, Munkhbileg B, Chen Q, Stanley NL, Guo K, Lapite A, Hausler R, Taylor DM, Corines J, Morrissette JJ, Lieberman DB, Yang G, Shestova O, Gill S, Zheng J, Smith-Simmer K, Banaszak LG, Shoger KN, Reinig EF, Peterson M, Nicholas P, Walne AJ, Dokal I, Rosenheck JP, Oetjen KA, Link DC, Gelman AE, Reilly CR, Dutta R, Lindsley RC, Brundige KJ, Agarwal S, Bertuch AA, Churpek JE, Tague LK, Johnson FB, Olson TS, Babushok DV. ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders , J Clin Invest, 135: 2025,e181659